Abstract
Despite advances in diagnosis and treatment of subarachnoid hemorrhage (SAH), combined morbidity and mortality rate in SAH patients accounted for greater than 50%. Many prognostic factors have been reported including delayed cerebral ischemia, cerebral vasospasm-induced infarction, and shunt-dependent hydrocephalus as potentially preventable or treatable causes. Recent experimental studies emphasize that early brain injury, a concept to explain acute pathophysiological events that occur in brain before onset of cerebral vasospasm within the first 72 h of SAH, may be more important than cerebral vasospasm, a classically important determinant of poor outcome, in post-SAH outcome. Galectin-3 is known for one of matricellular proteins and a mediator of inflammation in the central nervous system. Galectin-3 was also reported to contribute to poor outcomes in SAH patients, but the role of galectin-3 after SAH has not been determined. We produced experimental SAH mice, of which the top of the internal carotid artery was perforated by 4-0 monofilament, and evaluated effects of a galectin-3 inhibitor. We assessed neurological scores and brain water content at 24 h. The administration of a galectin-3 inhibitor significantly ameliorated brain edema and neuronal score in experimental SAH mice.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Suzuki H. What is early brain injury? Transl Stroke Res. 2015;6:1–3.
Fujimoto M, Shiba M, Kawakita F, Liu L, Shimojo N, Imanaka-Yoshida K, Yoshida T, Suzuki H. Deficiency of tenascin-C and attenuation of blood-brain barrier disruption following experimental subarachnoid hemorrhage in mice. J Neurosurg. 2016;124:1693–702.
Liu L, Fujimoto M, Kawakita F, Nakano F, Imanaka-Yoshida K, Yoshida T, Suzuki H. Anti-vascular endothelial growth factor treatment suppresses early brain injury after subarachnoid hemorrhage in mice. Mol Neurobiol. 2016;53:4529–38.
Liu L, Kawakita F, Fujimoto M, Nakano F, Imanaka-Yoshida K, Yoshida T, Suzuki H. Role of periostin in early brain injury after subarachnoid hemorrhage in mice. Stroke. 2017;48:1108–11.
Okada T, Suzuki H. Toll-like receptor 4 as a possible therapeutic target for delayed brain injuries after aneurysmal subarachnoid hemorrhage. Neural Regen Res. 2017;12:193–6.
Fujimoto M, Shiba M, Kawakita F, Liu L, Shimojo N, Imanaka-Yoshida K, Yoshida T, Suzuki H. Effects of Tenascin-C knockout on cerebral vasospasm after experimental subarachnoid hemorrhage in mice. Mol Neurobiol. 2018;55(3):1951–8. https://doi.org/10.1007/s12035-017-0466-x.
Burguillos Miguel A, Svensson M, Schulte T, Boza-Serrano A, Garcia-Quintanilla A, Kavanagh E, Santiago M, Viceconte N, Oliva-Martin Maria J, Osman Ahmed M, Salomonsson E, Amar L, Persson A, Blomgren K, Achour A, Englund E, Leffler H, Venero Jose L, Joseph B, Deierborg T. Microglia-secreted Galectin-3 acts as a Toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep. 2015;10:1626–38.
Nishikawa H, Nakatsuka Y, Shiba M, Kawakita F, Fujimoto M, Suzuki H. Increased plasma Galectin-3 preceding the development of delayed cerebral infarction and eventual poor outcome in non-severe aneurysmal subarachnoid hemorrhage. Transl Stroke Res. 2018;9(2):110–9. https://doi.org/10.1007/s12975-017-0564-0.
Altay O, Suzuki H, Hasegawa Y, Caner B, Krafft PR, Fujii M, Tang J, Zhang JH. Isoflurane attenuates blood-brain barrier disruption in ipsilateral hemisphere after subarachnoid hemorrhage in mice. Stroke. 2012;43:2513–6.
Ma Z, Han Q, Wang X, Ai Z, Zheng Y. Galectin-3 inhibition is associated with neuropathic pain attenuation after peripheral nerve injury. PLoS One. 2016;11:e0148792. https://doi.org/10.1371/journal.pone.0148792.
Vergaro G, Prud'homme M, Fazal L, Merval R, Passino C, Emdin M, Samuel JL, Cohen Solal A, Delcayre C. Inhibition of Galectin-3 pathway prevents isoproterenol-induced left ventricular dysfunction and fibrosis in mice. Hypertension. 2016;67:606–12.
Shen YF, Yu WH, Dong XQ, Du Q, Yang DB, Wu GQ, Zhang ZY, Wang H, Jiang L. The change of plasma galectin-3 concentrations after traumatic brain injury. Clin Chim Acta. 2016;456:75–80.
Yan XJ, Yu GF, Jie YQ, Fan XF, Huang Q, Dai WM. Role of galectin-3 in plasma as a predictive biomarker of outcome after acute intracerebral hemorrhage. J Neurol Sci. 2016;368:121–7.
Shin T. The pleiotropic effects of galectin-3 in neuroinflammation: a review. Acta Histochem. 2013;115:407–11.
Jeon SB, Yoon HJ, Chang CY, Koh HS, Jeon SH, Park EJ. Galectin-3 exerts cytokine-like regulatory actions through the JAK-STAT pathway. J Immunol. 2010;185:7037–46.
Kawakita F, Fujimoto M, Liu L, Nakano F, Nakatsuka Y, Suzuki H. Effects of Toll-like receptor 4 antagonists against cerebral vasospasm after experimental subarachnoid hemorrhage in mice. Mol Neurobiol. 2017;54(8):6624–33. https://doi.org/10.1007/s12035-016-0178-7.
Yip PK, Carrillo-Jimenez A, King P, Vilalta A, Nomura K, Chau CC, Egerton AM, Liu ZH, Shetty AJ, Tremoleda JL, Davies M, Deierborg T, Priestley JV, Brown GC, Michael-Titus AT, Venero JL, Burguillos MA. Galectin-3 released in response to traumatic brain injury acts as an alarmin orchestrating brain immune response and promoting neurodegeneration. Sci Rep. 2017;7:41689. https://doi.org/10.1038/srep41689.
Acknowledgments
We thank Ms. Chiduru Yamamoto, Department of Neurosurgery, Mie University Graduate School of Medicine, for providing technical assistance.
Conflict of interest: The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Nishikawa, H. et al. (2020). The Role of Galectin-3 in Subarachnoid Hemorrhage: A Preliminary Study. In: Martin, R., Boling, W., Chen, G., Zhang, J. (eds) Subarachnoid Hemorrhage. Acta Neurochirurgica Supplement, vol 127. Springer, Cham. https://doi.org/10.1007/978-3-030-04615-6_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-04615-6_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-04614-9
Online ISBN: 978-3-030-04615-6
eBook Packages: MedicineMedicine (R0)